

Niti Goel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/416071/niti-goel-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74
papers

2,118
citations

24
h-index

44
g-index

89
ext. papers

2,473
ext. citations

3.8
avg, IF

4.36
L-index

#	Paper	IF	Citations
74	Patient Perspectives on Long-Term Outcomes in Rheumatoid Arthritis. A Qualitative Study from the OMERACT Patient Outcomes in Longitudinal Studies Working Group.. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 152028	5.3	
73	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211057975	3.8	1
72	Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis. <i>Rheumatology and Therapy</i> , 2021 , 8, 327-346	4.4	4
71	Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 367-386	5.3	
70	Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 1547-1551	4.1	1
69	Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 607-617	5.3	1
68	Enhancing patient research partner engagement: Research in psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021 , 35, 101685	5.3	0
67	Outcomes Reported in Prospective Long-Term Observational Studies and Registries of Patients With Rheumatoid Arthritis Worldwide: An Outcome Measures in Rheumatology Systematic Review. <i>Arthritis Care and Research</i> , 2021 , 73, 649-657	4.7	2
66	Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 58-66	4.1	3
65	OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1117-1124	5.3	1
64	Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1113-1116	5.3	1
63	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1108-1112	5.3	2
62	Conducting research in psoriatic arthritis: the emerging role of patient research partners. <i>Rheumatology</i> , 2020 , 59, i47-i55	3.9	2
61	Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines. <i>Therapeutic Innovation and Regulatory Science</i> , 2020 , 54, 370-384	1.2	12
60	GRAPPA 2019 Project Report. <i>Journal of Rheumatology</i> , 2020 , 96, 53-57	4.1	6
59	Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice. <i>Therapeutic Innovation and Regulatory Science</i> , 2020 , 54, 324-341	1.2	22
58	Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1158-1181	5.3	4

57	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. <i>Journal of Rheumatology</i> , 2019 , 46, 1173-1178	4.1	3
56	Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019 , 46, 1164-1167	4.1	4
55	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019 , 46, 996-1005	4.1	21
54	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019 , 95, 33-37	4.1	9
53	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , 2019 , 95, 54-57	4.1	6
52	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019 , 46, 990-995	4.1	26
51	Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. <i>Pharmacology Research and Perspectives</i> , 2018 , 6, e00380	3.1	15
50	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 654-665	5.3	32
49	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018 , 94, 17-25	4.1	8
48	The effects of cultural background on patient-perceived impact of psoriatic arthritis - a qualitative study conducted in Brazil and France. <i>Advances in Rheumatology</i> , 2018 , 58, 33	3	3
47	Biosimilars in rheumatology: understanding the rigor of their development. <i>Rheumatology</i> , 2017 , 56, 187-197	3.9	26
46	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017 , 44, 1522-1528	4.1	66
45	Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group. <i>Journal of Rheumatology</i> , 2017 , 44, 1727-1733	4.1	5
44	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 673-680	2.4	138
43	The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 855-861	2.4	46
42	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017 , 44, 697-700	4.1	29
41	Tackling Patient Centricity: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 703-705	4.1	2
40	Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. <i>Journal of Rheumatology</i> , 2017 , 44, 1894-1898	4.1	8

39	Validating Rheumatoid Arthritis Remission Using the PatientsTPerspective: Results from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017 , 44, 1889-1893	4.1	12
38	Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. <i>Journal of Rheumatology</i> , 2017 , 44, 1916-1919	4.1	10
37	Recent Advances in Understanding of the Genetics of Antiphospholipid Syndrome 2017 , 53-75		
36	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016 , 43, 965-9	4.1	22
35	Let's Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016 , 43, 970-3	4.1	3
34	Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials. <i>Arthritis Care and Research</i> , 2016 , 68, 299-307	4.7	6
33	Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. <i>Journal of Rheumatology</i> , 2016 , 43, 203-7	4.1	18
32	Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , 2015 , 42, 2198-203	4.1	29
31	Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015 , 42, 1048-1051	4.1	6
30	Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective. <i>Journal of Rheumatology</i> , 2015 , 42, 1971-1975	4.1	14
29	Building Bridges between Researchers and Patient Research Partners: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015 , 42, 1021-1026	4.1	8
28	Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda. <i>Journal of Rheumatology</i> , 2015 , 42, 1934-1942	4.1	6
27	Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures. <i>Journal of Rheumatology</i> , 2015 , 42, 2448-59	4.1	15
26	Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials. <i>Trials</i> , 2015 , 16,	2.8	78
25	Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1206-11	4.1	12
24	Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11. <i>Journal of Rheumatology</i> , 2014 , 41, 782-91	4.1	30
23	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. <i>Rheumatology</i> , 2012 , 51, 2204-14	3.9	102
22	Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. <i>Rheumatology</i> , 2012 , 51, 1628-38	3.9	35

21	Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. <i>Rheumatology</i> , 2012 , 51, 1226-34	3.9	56
20	Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2203-8		11
19	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. <i>Current Medical Research and Opinion</i> , 2011 , 27, 315-25	2.5	12
18	Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1713-8	2.4	31
17	Certolizumab pegol. <i>MAbs</i> , 2010 , 2, 137-47	6.6	125
16	The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). <i>Osteoporosis International</i> , 2010 , 21, 713-22	5.3	10
15	Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 805-11	2.4	241
14	Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicine. <i>Journal of Rheumatology</i> , 2009 , 36, 2724-32	4.1	10
13	Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. <i>Osteoporosis International</i> , 2008 , 19, 1247-50	5.3	21
12	Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. <i>Arthritis and Rheumatism</i> , 2007 , 57, 318-26		124
11	Primary care house staff attitudes toward osteoporosis management. <i>Southern Medical Journal</i> , 2006 , 99, 461-6	0.6	5
10	Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment. <i>Osteoporosis International</i> , 2005 , 16, 1545-57	5.3	43
9	Mechanical sensation and pain thresholds in patients with chronic arthropathies. <i>Journal of Pain</i> , 2003 , 4, 203-11	5.2	93
8	Pericardial effusion and cardiomyopathy following arthritis with parvovirus B19 infection: response to intravenous immunoglobulin. <i>Journal of Clinical Rheumatology</i> , 2001 , 7, 346-9	1.1	2
7	Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance. <i>Arthritis and Rheumatism</i> , 1999 , 42, 318-27		56
6	Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. LUMINA Study Group. Lupus in Minority Populations, Nature versus Nurture. <i>Arthritis and Rheumatism</i> , 1999 , 12, 256-66		47
5	Comparison of an enzyme immunoassay to an indirect fluorescent immunoassay for the detection of antinuclear antibodies. <i>American Journal of Clinical Pathology</i> , 1999 , 111, 503-6	1.9	15
4	Systemic lupus erythematosus in three ethnic groups: IV. Factors associated with self-reported functional outcome in a large cohort study 1999 , 12, 256		1

3	Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1173-80		174
2	Antiphospholipid antibody syndrome: current concepts. <i>Hospital Practice (1995)</i> , 1998 , 33, 129-30, 133-5, 140, passim	2.2	7
1	Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1738-43		56